Modality
Fusion Protein
MOA
FGFRi
Target
FLT3
Pathway
Checkpoint
SCDSchizophrenia
Development Pipeline
Preclinical
~Sep 2016
→ ~Dec 2017
Phase 1
Mar 2018
→ Sep 2027
Phase 1Current
NCT08175990
2,806 pts·Schizophrenia
2018-08→2027-09·Recruiting
NCT06032492
518 pts·Schizophrenia
2018-03→TBD·Recruiting
3,324 total pts1 indication
Phase 2
Phase 3
NDA/BLA
Approved
CompletedCurrentUpcoming
Catalysts (1)
2027-09-031.4y awayPh2 Data· Schizophrenia
Trial Timeline
2018Q2Q3Q42019Q2Q3Q42020Q2Q3Q42021Q2Q3Q42022Q2Q3Q42023Q2Q3Q42024Q2Q3Q42025Q2Q3Q42026Q2Q3Q42027Q2Q3Q4
P1/2
Recruit…
P1/2
Recruit…
Catalysts
Ph2 Data
2027-09-03 · 1.4y away
Schizophrenia
Recruiting|StartCompletionToday
Trials (2)
| NCT | Phase | Indication | Status | N | EP |
|---|---|---|---|---|---|
| NCT08175990 | Phase 1/2 | Schizophrenia | Recruiting | 2806 | ACR20 |
| NCT06032492 | Phase 1/2 | Schizophrenia | Recruiting | 518 | ORR |
Competitors (10)
| Drug | Company | Phase | Target | MOA |
|---|---|---|---|---|
| JNJ-8168 | Johnson & Johnson | Phase 2/3 | FLT3 | |
| LLY-9749 | Eli Lilly | Phase 3 | C5 | |
| LLY-1956 | Eli Lilly | Phase 1/2 | BCMA | |
| Sotorapivir | Moderna | Approved | FLT3 | |
| SRP-9822 | Sarepta | Phase 3 | SOS1 | |
| Nidaratamab | Exelixis | Phase 3 | FLT3 | |
| Rimainavolisib | Illumina | Phase 2 | PD-1 | |
| Elrainavolisib | Roivant Sciences | Preclinical | Nectin-4 | |
| Zanumavacamten | Iovance | Phase 2 | FLT3 | |
| RAR-440 | Ultragenyx | Phase 2 | FLT3 |